Rebus Holdings Inc (RBSH)

[AAAAMHIM]

WRONGGGGGGG! Check EVERY SOCIAL network outlet u can. You won't find ONE trader talking about remsidivir or Corona virus related to NSPX. Imaginary opinions are cool but traders like REALITY. ACTUAL FACTS, things you can measure. I know MOST OF todays buyers. Heck one of my friends had 3.8 million on the .0105 bid (yes, not a misprint) but it ran too fast for him so he didn't get filled. We are laughing at your posts. Just give up already. LMFAAAAAOOOO! And to the guy blocking the .0129 ask today. We will see you tomorrow. Those shares will be tasty

NSPX .0119 oversold. This tiny FLOAT biotech once traded at $150+. UNKNOWN but not for long.

INSPYR THERAPEUTICS INC (NSPX) FUNDAMENTALS & COMPANY PROFILE

<><><><><>BREAKING NEWS!<><><><><><>

Inspyr Therapeutics: Can This High Potential Cancer Killing Biotech Repurpose Drugs to Help Fight COVID-19?
https://www.marketwatch.com/press-release/inspyr-therapeutics-can-this-high-potential-cancer-killing-biotech-repurpose-drugs-to-help-fight-covid-19-2020-03-24

"Inspyr merged with Lewis and Clark Pharmaceuticals several years ago and since then has developed a proprietary, industry-leading technology platform based on adenosine chemistry and biology and a broad pipeline of novel therapies.

Inspyr Therapeutics & Lewis and Clark Pharmaceuticals Complete Merger
https://drug-dev.com/inspyr-therapeutics-lewis-and-clark-pharmaceuticals-complete-merger/

Lewis and Clark Pharmaceuticals, Inc. (L&C Pharma) is an early stage drug development company focusing on adenosine receptor-based therapies for a wide range of inflammatory, autoimmune, and other underserved chronic diseases. L&C Pharma was founded in 2011 by Robert Thompson, Ph.D., an acknowledged world leader in adenosine chemistry. Dr. Thompson has assembled a team of leading experts in pre-clinical development, toxicology, and adenosine receptor pharmacology, physiology and molecular biology to develop novel compounds for chronic indications.

Inspyr Therapeutics, Inc. develops therapies for cancer using a novel technology platform that combines a powerful therapeutic (thapsigargin) with a patented prodrug delivery system that targets the release of drugs within solid tumors. Mipsagargin, its lead drug candidate, has been studied in a Phase 2 clinical trial in patients with Nexavar®-refractory hepatocellular carcinoma (HCC) and has been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in this indication. For additional information on Inspyr Therapeutics, visit www.inspyrtx.com.

Patents Assigned to Lewis and Clark Pharmaceuticals, Inc.
https://patents.justia.com/assignee/lewis-and-clark-pharmaceuticals-inc

Mipsagargin latest update as of June 2018 (with other patent info):

https://adisinsight.springer.com/drugs/800030883

https://patents.justia.com/assignee/inspyr-therapeutics-inc

The Company has fully-equipped, state-of-the-art organic and analytical chemistry laboratories located in Charlottesville, Virginia, where a team of chemists and toxicologists have expertise in chemical synthesis and analysis, non-clinical dose formulation, plasma concentration analysis, assay development, and toxicology.

MIPSAGARGIN- Inspyr’s drug that can potentially cure various cancers-

MUST WATCH videos about Mipsagargin:

Intro into Mipsagargin by Inspyr(formerly Genspera):

NSPX in the News- Mipsagargin Breakthrough Drug- Potential replacement for chemotherapy:
$NSPX Once traded at $150+ https://t.co/4xpVadG901